Top Markets
#1 MowCat MowCat +48.98%
#2 Velvet Velvet +25.75%
#3 Audiera Audiera +24.51%
#4 Bermuda Shorts Bermuda Shorts +24.25%
#5 Quack AI Quack AI +21.87%
#6 Derive Derive +19.57%
#7 aPriori aPriori +19.14%
#8 Biconomy Biconomy +16.79%
#9 SkyAI SkyAI +13.83%
#10 Geodnet Geodnet +13.01%
Coin of the day
MowCat MowCat
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Medigene AG Medigene AG

Medigene AG

MDG1
Rang in aandelen #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Aandeelprijs
$0.14942078
Laatst gesynchroniseerd: 2025-05-15
Marktkapitalisatie
$3.86M
Verandering (1 dag)
0.10%
Verandering (1 jaar)
0.00%
Land
DE
Handel Medigene AG (MDG1)

Categorie

Healthcare
P/S-ratio voor Medigene AG (MDG1)
P/S-ratio op August 2026 TTM: 0.33
Volgens de meest recente financiële rapporten en aandelenkoers van Medigene AG is de huidige P/S-ratio (TTM) 0.33. Eind 2022 had het bedrijf een P/S-ratio van 1.58.
P/S-ratiohistoriek voor Medigene AG van 2004 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 0.33 -94.44%
2023 5.86 270.74%
2022 1.58 -76.40%
2021 6.70 -37.67%
2020 10.75 15.55%
2019 9.30 -81.25%
2018 49.61 -30.09%
2017 70.97 -38.41%
2016 115.23 29.31%
2015 89.11 1,204.14%
2014 6.83 -18.93%
2013 8.43 -29.80%
2012 12.01 -23.25%
2011 15.64 -52.41%
2010 32.87 915.33%
2009 3.24 -25.83%
2008 4.36 -43.78%
2007 7.76 51.85%
2006 5.11 -35.56%
2005 7.93 -16.62%
2004 9.52 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 3,018.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 3,006.19%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 1,354.31%
BE